Alzinova

Alzinova R&D per Employee

R&D Spending per Employee of Alzinova (ALZ.ST) as of Oct 17, 2026.

R&D per Employee

-SEK

Last updated:

R&D Spending per Employee of Alzinova is 2026 - SEK. R&D Spending per Employee of Alzinova was 2025 - SEK. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alzinova Stock analysis

What does Alzinova do? Alzinova AB, based in Mölndal, Sweden, operates in the Health Care sector, specializing in biotechnology. The company focuses on researching and developing drugs for Alzheimer's disease treatment, particularly an oligomer-directed vaccine (ALZ-101) and diagnostics using a monoclonal antibody (ALZ-201). Both products target oligomeric Aβ, which damages brain synapses. Listed on 25 November 2015, Alzinova is dedicated to innovative therapeutic solutions for neurodegenerative conditions. Alzinova is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alzinova stock

On Eulerpool you can find the complete historical development of R&D Spending per Employee Alzinova since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Alzinova historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Alzinova

All Key Metrics — Alzinova